Harvard Bioscience, Inc.

HBIO - Financial Snapshot

Healthcare sector | Medical Instruments & Supplies industry

View on:
Ranks:

Metrics for HBIO

Price $6.4
Shares Outstanding 4.51M
All-Time Low $0.28
52-Week Low $0.28

Balance Statement Metrics

Net Cash / Share $0
cashValuePerShare = (Cash + Short Term Investments - Total Liabilities) / Shares Outstanding
⇒ cashValuePerShare = ((8,614,000 - 66,337,000) / 4,510,217) = -12.7983
Net Current Assets / Share $-4.02
netCurrentAssetsPerShare = (Current Assets - Total Liabilities) / Shares Outstanding
⇒ netCurrentAssetsPerShare = ((48,225,000 - 66,337,000) / 4,510,217) = -4.0158
Net Tangible Assets / Share $0
netTangibleAssetsPerShare = (Total Assets - Intangibles - Total Liabilities) / Shares Outstanding
⇒ netTangibleAssetsPerShare = ((80,071,000 - 17,198,000 - 66,337,000) / 4,510,217) = -0.77
Avg CA Burn (Quarterly %) 10.09% (as of 5-5-2026)

Earning Metrics

Max Earning Power / Share $1.06
maxEarningPowerPerShare = (EBITDA / EP_MULTIPLIER) / Shares Outstanding
⇒ maxEarningPowerPerShare = ((504,000 / 0.105) / 4,510,217) = 1.0643
Adjusted Earning Power $-6.01
adjustedEarningPower = (Net Income / EP_MULTIPLIER) / Shares Outstanding
⇒ adjustedEarningPower = ((-2,847,000 / 0.105) / 4,510,217) = -6.0117
Non-Cash Charges to Market Cap 4.68%
nonCashChargeToMKTCAP = Non-Cash Charges / Market Capitalization
Data as of: Price 05-04-26 16:00 ET, Balance Sheet 2025-12-31, Income Statement 2025-12-31, Cash Flow 2025-12-31

Indicators

Dividend indicators Value Date
Current Dividend Streak No 5-5-2026
Consecutive Years Paid No 5-5-2026
Pays Dividend No 5-5-2026
Income indicators Value Date
Current Dividend Streak No 5-5-2026
EBITDA Positive Yes 5-5-2026
Net Income Positive No 5-5-2026

Metric History Explorer

Pick a metric to view its history table and chart.

Tangible Book Value Per Share History

Formula: Tangible Book Value / shares from balance statements. Includes 2 quarterly.

Chart plots one TBV / Share point per report date (duplicate same-date annual/quarterly rows are merged).

Report Date Period TBV / Share Tangible Book Value Shares Used
2025-12-31 Quarterly $-0.77 -3.5M ($-3,464,000) 4.5M (4,471,989)
2025-09-30 Quarterly $-0.09 -3.8M ($-3,836,000) 44.6M (44,579,665)

Dividend Payments

Historical cash dividends per share from Yahoo ex-dividend dates.

Date Dividend / Share
No dividend payment history available yet

Shares Outstanding Changes

Date Shares Outstanding Delta
2026-04-23 4,510,217 +38,228
2026-03-24 4,471,989 -39,707,905
2026-03-16 44,179,894 -540,000

Short Interest Changes

Latest short-interest change: 243,452 shares (5.49% of float) | Days to cover: 3.05

Date Short Interest Delta Δ %
2026-04-27 243,452 shares +158,693 +187.23%
2026-04-17 84,759 shares +37,454 +79.18%
2026-03-25 47,305 shares +1,933 +4.26%
2026-03-16 45,372 shares -408,354 -90.00%

Interesting Volume Days

Volume/ratio use shares outstanding as of the event date (frozen).

Date Volume Shares Outstanding Volume / Shares Price
No interesting volume events

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.